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Transcription factorsPiperlongumine (PL), a pepper plant alkaloid from Piper longum, has anti-inﬂammatory and anti-cancer
properties. PL selectively kills both solid and hematologic cancer cells, but not normal counterparts. Here
we evaluated the effect of PL on the proliferation and survival of B-cell acute lymphoblastic leukemia
(B-ALL), including glucocorticoid (GC)-resistant B-ALL. Regardless of GC-resistance, PL inhibited the pro-
liferation of all B-ALL cell lines, but not normal B cells, in a dose- and time-dependent manner and
induced apoptosis via elevation of ROS. Interestingly, PL did not sensitize most of B-ALL cell lines to dex-
amethasone (DEX). Only UoC-B1 exhibited a weak synergistic effect between PL and DEX. All B-ALL cell
lines tested exhibited constitutive activation of multiple transcription factors (TFs), including AP-1, MYC,
NF-jB, SP1, STAT1, STAT3, STAT6 and YY1. Treatment of the B-ALL cells with PL signiﬁcantly downregu-
lated these TFs and modulated their target genes. While activation of AURKB, BIRC5, E2F1, and MYB
mRNA levels were signiﬁcantly downregulated by PL, but SOX4 and XBP levels were increased by PL.
Intriguingly, PL also increased the expression of p21 in B-ALL cells through a p53-independent mechan-
ism. Given that these TFs and their target genes play critical roles in a variety of hematological malignan-
cies, our ﬁndings provide a strong preclinical rationale for considering PL as a new therapeutic agent for
the treatment of B-cell malignancies, including B-ALL and GC-resistant B-ALL.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
ALL is the most common childhood cancer, accounting for
approximately 30% of all childhood malignancies in North America
[1]. Although the majority of children with ALL are cured, relapsed
ALL remains a leading cause of cancer-related deaths in children
[2]. Approximately 20% of patients become resistant to GC during
the treatment of B-ALL and up to 80% of relapsed patients are
classiﬁed as being GC-resistant [3]. Despite the critical importance
of developing new treatments for childhood ALL, especiallyGC-resistant ALL, many factors impede drug discovery and
development.
Herbal remedies based on medicinal or dietary plants are
becoming increasingly popular in the world [4]. Various phyto-
chemicals, which are reported to regulate molecular signal trans-
duction pathways capable of inducing cell death, are now a
major focus of research. Importantly, many FDA-approved antican-
cer therapeutic agents are derived from phytochemicals. Paclitaxel,
one of the newest FDA-approved anticancer therapeutic agents,
was isolated from the bark of Paciﬁc Yew trees [5].
Piperlongumine (PL), one of the primary constituents isolated
from the fruit of the long pepper, Piper longum Linn [6], has antitu-
mor, antioxidant, antibacterial, antifungal and antiinﬂammatory
properties [7]. Interest in PL as a potential cancer drug has drawn
attention since Raj et al. [8] reported that PL selectively kills
human solid tumor cells, but not their normal non-transformed
counterparts. We previously reported that PL selectively kills
Burkitt lymphoma (BL) cells by inhibiting the LMP1-NF-jB-MYC
axis and their downstream target genes [9,10]. To extend our
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of PL and its underlying molecular mechanisms, focusing on TFs
and their downstream target genes, on the growth and survival
of B-ALL and GC-resistant B-ALL.
2. Materials and methods
2.1. Chemicals and B-ALL cell lines
PL was purchased from INDOFINE (Hillsborough, NJ), dissolved
in dimethyl sulfoxide (DMSO). Dexamethasone (DEX), Buthionine
sulfoximine (BSO), dithiothreitol (DTT) were purchased from
Sigma (St. Louis, MO) and dissolved in Ethanol or distilled water.
Five GC-resistant B-ALL cell lines, HAL-01, RCH-ACV, Reh, SEM
and UoC-B1 and four GC-sensitive B-ALL cell lines, 697, NALM6,
RS;11 and SUP-B15 were obtained from Dr. Pufall (Univ. of Iowa)
and maintained, at 37 C and 5% CO2, in RPMI 1640 medium with
10% fetal bovine serum. Human peripheral blood mononuclear cell
(PBMC) B cells were isolated from leukoreduction system cham-
bers generated by the University of Iowa Blood Center using centri-
fugation through a Ficoll-Hypaque cushion and CD45R (B220)
microbeads and MACS separation columns (Miltenyi, Auburn,
CA).
2.2. Cell growth and proliferation
Growth and proliferation of B-ALL cells were determined with
the Cell Titer 96 MTS/PMS assay (Promega, Madison, WI). Brieﬂy,
1  105 cells were re-suspended in 100 ll growth medium and pla-
ted into 96-well plates (Costar, Cambridge, MA). 20 ll MTS/PMS
solution was added to each well 4 h before measurement at the
absorbance at 490 nm using a Multiskan Spectrum 96-well plate
spectrophotometer (Thermo Scientiﬁc, Hudson, NH).
2.3. Apoptosis
Programmed cell death was evaluated with the help of the try-
pan blue exclusion (TBE) and DNA fragmentation assays. For both
assays, 10  106 cells were treated with PL(at IC50) or left untreated
for 24 h at 37 C and 5% CO2. Cells were harvested and resuspended
in PBS. For TBE assay, 4 parts of 0.4% trypan blue solution were
mixed to 1 part of cell suspension, and the proportion ofFig. 1. PL induced growth inhibition and apoptosis of all B-ALL cell lines regardless o
Proliferation was measured by MTS assay as described at Section 2. (B) The IC50 concent
DNA fragmentation assay (D). Cells (5  105/ml) were treated with PL as indicated for 24
Error bars shows the standard deviation from data represent the mean of triplicate deteblue-staining (dead) cells was determined using a hemocytometer.
Results are expressed as a percentage of the number of live cells
divided by the number of total cells. For DNA fragmentation assay,
DNA was extracted using the Puregene Cell kit (Gentra Systems,
Minneapolis, MN) followed by electrophoretic fractionation on
1.0% agarose gels containing ethidium bromide.
2.4. Preparation of nuclear extract
Pellets of 10  106 cells were lysed in 400 ll buffer A (10 mM
KCl, 0.2 mM EDTA, 1.5 mM MgCl2, 0.5 mM DTT and 0.2 mM PMSF)
at 4 C for 10 min. Lysate was centrifuged for 5 min at 14,000g
and supernatant was stored at 70 C as cytosolic extract. The resi-
dual pellet was resuspended in 100 ll of ice-cold buffer C (20 mM
HEPES [pH 7.9], 420 mM NaCl, 1.5 mM MgCl2, 20% [v/v] glycerol,
0.2 mM EDTA, 0.5 mM DTT and 0.2 mM PMSF). After incubation
at 4 C for 20 min, the lysate was centrifuged for 6 min at
14,000g and the supernatant was stored at 70 C as nuclear
extract (NE). Protein concentrations of NE were determined with
the help of the BCA kit (Bio-Rad, Richmond, CA).
2.5. Electrophoretic mobility shift assay (EMSA)
EMSA was carried out in a ﬁnal volume of 25 ll binding buffer
(10 mM Tris [pH 7.5], 100 mM NaCl, 1 mM DTT, 1 mM EDTA, 4%
[w/v] glycerol, 0.1 mg/ml sonicated salmon sperm DNA), 10 lg
nuclear extract, and radiolabeled oligonucleotide that contained
consensus AP-1, MYC, NF-jB, p53, SP1, STAT1, STAT3, STAT4,
STAT6 or YY1 binding site (Santa Cruz Biotechnology, Santa Cruz,
CA). Oligonucleotide was end-labeled to a speciﬁc activity of 105
CPM using c-[32P]-ATP and T4-polynucleotide kinase and puriﬁed
on a Nick column (GE Healthcare, Piscataway, NJ). Reaction mix-
tures were incubated at room temperature for 20 min and then
loaded on 6% non-denaturing polyacrylamide gels after 2 ll of
0.1% bromophenol blue was added. Gels were dried and subjected
to autoradiography.
2.6. Reverse transcription (RT) and quantitative polymerase chain
reaction (qPCR) assays
For RT, total RNA was extracted using the TRIzol (Sigma–
Aldrich, St. Louis, MO) and cDNA synthesis with 1 lg RNA andf GC-resistance. (A) Cells (1  106/ml) were treated with PL as indicated for 24 h.
ration of PL for each B-ALL cell lines. Apoptosis was measured by TBE assay (C) and
h and then subjected to TBE or DNA fragmentation assay as described at Section 2.
rminations.
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qPCR relied on the TaqMan universal PCR master mix from Applied
Biosystems (Carlsbad, CA) and – after 1 cycle of 50 C for 2 min and
1 cycle of 95 C for 10 min – 40 cycles of DNA ampliﬁcation at 66 C
(1 min) and 95 C (15 s). Internal probes were labeled with the
ﬂuorescent reporter dye, 6-carboxyﬂuorescein (6-FAM), on the 50
end and the quencher dye, Black Hole (BHQ), on the 30 end. The
sequence of gene-speciﬁc PCR primers listed in Supplementary
Table 1. Amplicons were generated and analyzed using the
Applied Biosystems 7900 HT device and ABI SDS v 2.3 software
(Applied Biosystems, Carlsbad, CA), respectively. Gene expression
was compared to Hprt message, which was used as control. Gene
expression levels in BL cells were compared to expression levels
in human PBMC B cells and presented as fold gene expression
change.Fig. 2. (A) PL caused apoptosis by elevation of ROS. Cells (1  106/ml) were treated with
for 24 h or 48 h. (B) PL sensitizes only UoC-B1 cell line to DEX but not in others. Cells (
susceptibility individually or combination of them as indicated for 24 h or 48 h. Prolifer
standard deviation from data represent the mean of triplicate determinations.3. Results
3.1. PL inhibits proliferation of B-ALL cell lines irrespective of
GC-resistance
To evaluate whether PL inhibits the proliferation of B-ALL cells,
ﬁve GC-resistant B-ALL cell lines (HAL-01, RCH-ACV, Reh, SEM and
UoC-B1) and four GC-sensitive B-ALL cell lines (697, NALM6, RS;11
and SUP-B15) were treated with various concentrations of PL
(2.5–20 lM) for 24 h or 48 h and then cell proliferation was quan-
tiﬁed using the MTS assay. As shown in Fig. 1A, PL inhibited the
growth of all cell lines in a dose- and time-dependent (Supplemen-
tary Fig. 1) manner, irrespective of GC-resistance. The IC50 values
for PL ranged between 3.9 lM and 7.7 lM (Fig. 1B) and, in subse-
quent experiments, PLwas used at the IC50 speciﬁc for each cell line.PL(IC50), 1 mM BSO or 200 lM DTT individually or combination of them as indicated
1  106/ml) were treated with low dose of PL or DEX depending on each cell line’s
ation was measured by MTS assay as described at Section 2. Error bars shows the
Fig. 3. (A) Status of DNA-binding activity of TFs and (B) PL-induced repression of constitutively activated TFs in B-ALL cells. EMSA was performed with NE from each B-ALL
cell line (1  106/ml) in the absence or presence of PL(IC50) for 24 h as described at Section 2.
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normal B cells
We then examined whether PL selectively kills B-ALL cells rela-
tive to normal PBMC B cells. B-ALL cells and normal PBMC B cells
were treated for 24 h with PL (2.5–20 lM) and the proportion of
viable cells was determined using the TBE assay. While PL effec-
tively killed B-ALL cells in a dose-dependent manner (Fig. 1C), nor-
mal PBMC B cells were largely unaffected by the drug. Apoptotic
cell death of the PL-treated B-ALL cells was conﬁrmed by DNA frag-
mentation analysis (Fig. 1D). These results demonstrated that PL
selectively killed B-ALL cells, but not normal PBMC B cells through
apoptosis.
3.3. PL causes apoptosis by elevating ROS via modulating GSH level
PL can induce apoptosis in cancer cells by reducing glutathione
(GSH) levels, which results in elevated levels of reactive oxygen
species (ROS) [8]. Consequently, we next investigated the effect
of PL on GSH and ROS in B-ALL cells. Inhibition of GSH by BSO,
which blocks GSH synthesis, synergistically increased PL-mediated
growth inhibition in B-ALL cells. However, treatment with DTT,
which maintains reduced GSH levels, completely abolished the
inhibitory effect of PL (Fig. 2A and Supplementary Fig. 2A). Thus,
we conﬁrmed that PL induces apoptosis of B-ALL cells by increas-
ing ROS through regulating GSH level.
3.4. PL does not sensitize majority of B-ALL cells to DEX
Next, we examined whether PL can sensitize B-ALL cells, parti-
cularly GC-resistant cells, to DEX. B-ALL cells were treated with PL
and DEX, alone or in combination, at low doses that cause only a
modest growth inhibition when used as single agents. As shown
in Fig. 2B and Supplementary Fig. 2B, a weak synergistic effect
between PL and DEX was only observed in UoC-B1 cells, but not
in other B-ALL cell lines. This result demonstrates that PL does
not sensitize B-ALL cells to DEX. The effect of DEX on the prolifera-
tion of B-ALL cells is presented in Supplementary Fig. 3.
3.5. PL represses constitutive activation of various TFs that play critical
role in the proliferation of normal and neoplastic B-lymphocytes
The aberrant deregulation of TF(s) is associated with various
types of cancer [11]. To test whether the proliferation and survivalof B-ALL is a result of constitutive activation of TF(s), we investi-
gated the DNA-binding activity of the following TFs in B-ALL cells
using EMSA: AP-1, MYC, NF-jB, p53, SP1, STAT1, STAT3, STAT4,
STAT6 and YY1. All B-ALL cell lines exhibited constitutive activa-
tion of AP-1, MYC, NF-jB, SP1, STAT1, STAT3, STAT6 and YY1,
whereas p53 and STAT4 showed basal levels or no binding activity
compared to the normal, control PBMC B cells (Fig. 3A). This result
led us to investigate whether PL inhibits the constitutive activation
of these TFs. As shown in Fig. 3B, PL dramatically inhibited the con-
stitutive activation of TFs in all B-ALL cell lines. Interestingly, the
basal level of DNA-binding activity of p53 and STAT4 did not
change with PL treatment. These results suggested that PL inhibits
the constitutive activation of multiple TFs critical for the prolifera-
tion and survival of B-ALLs.3.6. PL changes expression of target genes of these TFs
Next, we evaluated the expression of ﬁfty genes previously
implicated as targets of these TFs to identify which genes were
involved in PL-induced apoptosis. AURKB/Aurora kinase B, BIRC5/
Survivin, E2F1 and MYB were signiﬁcantly downregulated in
B-ALL cells (Fig. 4A) after PL(IC50) treatment for 24 h. In contrast,
expression of SOX4, XBP1 and CDKN1A/p21 were upregulated
(Fig. 4B) with PL(IC50) treatment. Next, we used qPCR and EMSA
to determine whether the elevated expression of p21 in the pre-
sence of PL was dependent on p53. Interestingly, we did not ﬁnd
any change in the level of p53 mRNA (Fig. 4B) or DNA-binding
activity of the protein (Fig. 4C) by PL treatment. These results
indicate that the elevation of p21 is independent of p53. Somewhat
unexpectedly, BCL family genes, including BAX, BCL2, and BCL2A1/
BFL1, were not affected by PL though BCLxL and BCL2A11/BIM
exhibited insigniﬁcant elevation compared to normal PBMC B cells
(Supplementary Fig. 4). These results indicate that PL-mediated
suppression of the TFs results in the modulation of target genes
known to be important for the proliferation and survival of B-ALL
cells.4. Discussion
Although more than 85% of children with ALL are cured,
relapsed and/or nonresponsive ALL remains a leading cause of can-
cer-related death in children and young adults [2]. Despite the pro-
mising potential of PL in cancer therapy, its effect on the growth
Fig. 4. PL disrupts the expression of target genes of these TFs. (A) Upregulated genes by PL. (B) Downregulated genes by PL. mRNA level of each gene in the absence or
presence of PL twere analyzed using qPCR as described at Section 2. Data were normalized to Hprt and converted to fold gene expression change by dividing the normalized
value from each cell line or by that of normal PBMC B cells. Error bars represent the standard deviation from a representative experiment performed in triplicate. (C) Basal
level of p53 DNA-binding activity was not affected by PL treatment. EMSA was performed with NE from each B-ALL cell line (1  106/ml) in the absence or presence of PL(IC50)
for 24 h as described at Section 2.
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unknown and the focus of this work. We found that PL inhibited
growth of B-ALL cell lines in a dose- and time-dependent manner
regardless of GC-resistance (IC50 of 3.9–7.7 lM). This result is con-
sistent with our recent report that the IC50 range for PL in human
BL cell lines is 2.8–8.5 lM [9] and is 5.1–9.0 lM for mouse BL cell
lines [10]. Interestingly, no difference in susceptibility to PL
between GC-resistant and -sensitive cell lines was observed. In line
with our recent ﬁndings for BL, PL selectively killed B-ALL cells, but
not normal PBMC B cells [9,10]. Similarly, in accordance with pre-
vious reports [8,9], we also conﬁrmed in B-ALL cells that PL causes
growth inhibition and apoptosis through elevation of ROS. Since
the biggest hurdle to treat B-ALL patients is the increase of
GC-resistance and relapse of B-ALL cells [2,3], we evaluated
whether PL can sensitize B-ALL cells, especially GC-resistant cells,
to DEX. Although GC-resistant cell lines, HAL-01 or UoC-B1 exhib-
ited additive or weak synergistic growth inhibition, the other cell
lines did not. These results demonstrate that PL does not sensitize
most B-ALL cell lines to DEX.Deregulation of signal transduction pathways are implicated in
the development of cancer [5]. We determined that AP1, MYC,
NF-jB, SP1, STAT1, STAT3, STAT6 and YY1 are activated in B-ALL
compared to normal B-cells. Remarkably, PL repressed the consti-
tutive activation of these TFs. Activation of these TFs in a variety
of tumors including leukemia is consistent with reports from the
literature [12–15] and inhibition of these constitutively activated
these TFs can lead to apoptosis [12,13,15]. Moreover, numerous
reports demonstrate that TFs act coordinately in the development
of cancer [9,10,15,16], which supports our ﬁnding that PL causes
apoptosis in B-ALL cells by inhibiting a network of TFs, rather than
the suppression of one or two TF(s).
Since TFs have the ability to alter global transcriptional proﬁles
[17], we validated a set of 50 target genes by qPCR. AURKB/Aurora
kinase B, BIRC5/Survivin, E2F1, and MYB exhibited elevated levels
in B-ALL cells relative to normal B-cells and were signiﬁcantly
downregulated by PL. AURKB [18] and Survivin [19] are overex-
pressed in many cancers and inhibition of these proteins results
in apoptosis [20]. E2F1 is a direct target gene of MYC and important
674 S.-S. Han et al. / Biochemical and Biophysical Research Communications 452 (2014) 669–675for NF-jB-dependent survival of tumor cells [21]. MYB, a direct
target of NF-kB [22], is a transcriptional activator whose
abrogation in cancer cells causes apoptosis [23]. In contrast, PL
signiﬁcantly upregulated SOX4, XBP1 and p21. Several reports sup-
port the potential role of these genes in PL-mediated apoptosis. For
example, SOX4 is overexpressed in an ATM/ATR-dependent but
p53-independent manner [24] and activates apoptosis [17]. Inter-
estingly, SOX4 can directly repress NF-jB p50 at transcriptional
level [25] and also interacts with a number of TFs to synergistically
activate proapoptotic and antiproliferative SOX4 target genes [26].
NF-jB can regulate XBP-1 by inhibition of miR-214, which is a
negative regulator of XBP-1 [27]. Conversely, Xbp1 suppresses
intestinal tumorigenesis by inhibition of NF-jB and STAT3 [28].
Capsaicin [29] killed cancer cells by increase of XBP1 at the tran-
scriptional or protein level. Consequently, in accordance with these
reports, the genes identiﬁed in this work are likely to be critical
downstream targets of the altered TF proﬁle induced by PL.
Interestingly, p21 was elevated in B-ALL cell lines compared to
normal B-cells and its expression was further augmented by PL in a
p53-independent mechanism. Considering the accumulation of
evidence for a p53-independent role of p21 in cancer [30], activa-
tion of p21 is not unexpected in B-ALL. NF-jB-mediated activation
of p21 is critical to avoid p53-induced apoptosis and the initiation
and maintenance of leukemogenesis [31]. RelB [32] and STATs,
including STAT3 [33], regulate the oncogenic function of p21 at
the transcriptional level [32]. In accordance with these reports,
constitutive activation of NF-jB and STAT3 in B-ALL cells is likely
driving this anti-apoptotic program. However, PL increased p21
expression without a change in p53 status. In fact, the level of
p53 DNA-binding activity was unchanged even at a higher dose
of PL(IC75). Although activation of p21 is often regulated by p53,
p21 can act as a master effector of several tumor suppressor path-
ways in a p53-independent manner. Depending on the cellular
context and circumstances, p53-independent activation of p21 as
a tumor repressor is controlled by several TFs, including SP1 and
STATs [33]. Therefore, our ﬁnding that PL induces a p53-
independent activation of p21 suggests that the function of p21
may be switched from antiapoptotic to proapoptotic by treatment
with PL. However, the precise mechanism of how this switch in
p21 function occurs needs to be investigated in further detail.
In summary, PL causes growth inhibition and apoptosis in B-ALL
cells, irrespective of GC-resistance, by downregulation of multiple,
constitutively activated TFs, including AP1, MYC, NF-kB, SP1,
STAT1, STAT3 STAT6 and YY1. Although further studies are
required to fully understand the mechanism of PL-induced B-ALL
apoptosis, the results here demonstrate that PL could be a new
therapeutic agent for the treatment of malignant B-cell tumors
including B-ALL and GC-resistant B-ALL.Competing interests
Authors declare no competing interests.
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